Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 April 1994Website:
http://www.avidbio.comNext earnings report:
06 September 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:32:09 GMTDividend
Analysts recommendations
Institutional Ownership
CDMO Latest News
Avid Bioservices, Inc. (NASDAQ:CDMO ) Q4 2024 Earnings Conference Call July 2, 2024 4:30 PM ET Company Participants Tim Brons - IR, Vida Strategic Partners Nick Green - President & CEO Dan Hart - CFO Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Jacob Johnson - Stephens Paul Knight - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Max Smock - William Blair Operator Thank you for standing by, and welcome to the Avid Bioservices Fourth Quarter Fiscal Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million --
Paris – June 18, 2024 – EUROAPI announces today the implementation of a 5-year development and manufacturing agreement with Priothera, a biotechnology company specializing in molecules for the treatment of hematological malignancies and for the improvement of CAR-T cell therapies. Priothera is headquartered in Dublin, Ireland, and has a subsidiary in Saint-Louis (Haut-Rhin), France.
TUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company has achieved a Committed Badge from EcoVadis, one of the world's most trusted providers of business sustainability ratings. Avid earned a score of 56 from EcoVadis, placing the company in the 62nd percentile globally.
Pomerantz LLP is conducting an investigation for investors of Avid Bioservices, Inc. (NASDAQ: CDMO). Investors with claims are encouraged to reach out to Danielle Peyton at [email protected] or 646-581-9980, ext.
Avid Bioservices, Inc. (NASDAQ: CDMO) Q3 2024 Earnings Conference Call on April 29, 2024 at 4:30 PM ET featuring Tim Brons, Nick Green, Dan Hart, and Matt Kwietniak. Conference call participants include Jacob Johnson, Sean Dodge, Matt Hewitt, Max Smock, and Paul Knight. Operator welcomes everyone to the Avid Bioservices Third Quarter Fiscal 2024 Financial Results Conference Call where all participants are currently in a listen-only mode.
Avid Bioservices (NASDAQ: CDMO ) stock is falling on Thursday after the contract development and manufacturing company announced the pricing of a private placement. The private placement includes 7.00% Convertible Senior Notes due 2029 with an aggregate principal amount of $160 million.
Avid Bioservices has invested heavily in building new facilities, causing lower margins and negative free cash flow. The company's recent expansion projects have increased its revenue capacity to $400 million, with expected adjusted EBITDA margins in the low to mid 30s. Despite the investments, the company's guidance for the current fiscal year implies limited growth due to a shift in project types and the new facility not being fully operational yet.
Avid Bioservices (NASDAQ: CDMO ) stock is falling on Friday following the release of its earnings report for its fiscal second quarter of 2024. Avid Bioservices reported adjusted earnings per share of -12 cents alongside revenue of $25.4 million.
Avid Bioservices (NASDAQ: CDMO ) just reported results for the second quarter of 2024. Avid Bioservices reported earnings per share of -12 cents.
- 1(current)
What type of business is Avid Bioservices?
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
What sector is Avid Bioservices in?
Avid Bioservices is in the Healthcare sector
What industry is Avid Bioservices in?
Avid Bioservices is in the Biotechnology industry
What country is Avid Bioservices from?
Avid Bioservices is headquartered in United States
When did Avid Bioservices go public?
Avid Bioservices initial public offering (IPO) was on 04 April 1994
What is Avid Bioservices website?
https://www.avidbio.com
Is Avid Bioservices in the S&P 500?
No, Avid Bioservices is not included in the S&P 500 index
Is Avid Bioservices in the NASDAQ 100?
No, Avid Bioservices is not included in the NASDAQ 100 index
Is Avid Bioservices in the Dow Jones?
No, Avid Bioservices is not included in the Dow Jones index
When does Avid Bioservices report earnings?
The next expected earnings date for Avid Bioservices is 06 September 2024